Ender Ödemiş

Prof. Dr. Ender Ödemiş


Research Focus & Metrics

Academic Career Length

14Years (2013-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
12 January 2014 in Pediatric Cardiology
Verified
Journal Article
Closed access
PDF file
EÖEnder Ödemiş
Ender Ödemiş
MSMurat Saygi
Murat Saygi
AGAlper Guzeltas
Alper Guzeltas
ITI. Cansaran Tanidir
I. Cansaran Tanidir
YEYakup Ergul
Yakup Ergul
IBIhsan Bakir
Ihsan Bakir

10 December 2021 in Cardiology in the Young
Verified
Journal Article
Open access
PDF file
EÖEnder Ödemiş
Ender Ödemiş
IYIrem Yenidogan
Irem Yenidogan
The rate of morbidity and mortality related to pulmonary regurgitation and pulmonary stenosis are big concerns after the surgery for CHD. Percutaneous pulmonary valve implantation has been established as a less invasive technique compared to surgery with promising results according to long-term follow-up of the patients. There are only two approved valve options for percutaneous pulmonary valve implantation until now, which are Melody (Medtronic, Minneapolis, Minn, USA) and Sapien (Edwards Lifesciences, Irvine, Ca, USA). Both valves have limitations and do not cover entire patient population. Therefore, the cardiologists need more options to improve outcomes with fewer complications in a such promising area. Herein, we present a case series applying for pulmonary position in conduits and native right ventricular outflow tract of a new transcatheter valve system Myval ® which is designed for transcatheter aortic valve implantation procedures. This is the first patient series in which the use of Myvalv in dysfunctional right ventricular outflow tracts is described, after surgical repair of CHD.

16 November 2022 in Cardiology in the Young
Verified
Journal Article
Open access
PDF file
EÖEnder Ödemiş
Ender Ödemiş
IYIrem Yenidogan
Irem Yenidogan
MKMete Han Kizilkaya
Mete Han Kizilkaya
Objective: The purpose of this study is to assess the feasibility, effectivity, and safety of a novel self-expandable valve system, Pulsta® transcatheter heart valve in patients with tetralogy of fallot and severe pulmonary regurgitation after transannular patch repair.Background: Severe pulmonary regurgitation after tetralogy of fallot repair is a life-threatening problem and should be treated by pulmonary valve implantation. Although percutaneous pulmonary valve implantation has been ever increasingly used for this purpose, available balloon-expandable valves have limitations and cannot be used by most patients. Pulsta® transcatheter heart valve is a new self-expandable valve system and offers a new solution to be used in patients with different types of native right ventricular outflow tract geometry.Patients and Methods: Ten patients with severe regurgitation after tetralogy of fallot repair with a transannular patch have been enrolled in the study according to echocardiographic examination. MRI was used in asymptomatic patients to delineate the indication and the right ventricular outflow tract geometry. Pulsta® transcatheter heart valve implantation was performed in ten patients, and preprocedural, procedure, and 6 months follow-up findings of the patients were evaluated.Results: Pulsta® pulmonary valve implantation was performed in ten patients successfully without any severe complications. Valve functions were perfect in six of ten patients, while the others had insignificant regurgitation by echocardiographic examination at the end of 6 months follow-up.Conclusions: This study showed that Pulsta® transcatheter heart valve is a feasible, effective, and safe method in the treatment of severe pulmonary regurgitation due to transannular patch repair in patients with tetralogy of fallot.

11 January 2013 in Artificial Organs
Verified
Journal Article
Closed access
PDF file
EÖEnder Ödemiş
Ender Ödemiş
IOIsa Ozyilmaz
Isa Ozyilmaz
AGAlper Guzeltas
Alper Guzeltas
EEErsin Erek
Ersin Erek
SHSertac Haydin
Sertac Haydin
İBİhsan Bakır
İhsan Bakır

24 April 2025 in Catheterization and Cardiovascular Interventions
Verified
Journal Article
Closed access
BKBerk Kabadayı
Berk Kabadayı
ZEZeynep Bengi Eren
Zeynep Bengi Eren
EÖEnder Ödemiş
Ender Ödemiş

16 November 2022 in Cardiology in the Young
Verified
Journal Article
Open access
PDF file
EÖEnder Ödemiş
Ender Ödemiş
MKMete Han Kizilkaya
Mete Han Kizilkaya
Background: Transcatheter closure of perimembranous ventricular septal defects is challenging. Double disk-designed devices have high adverse event rates; therefore, research into new devices persists. One such devise is the LifetechTM Konar-MF Occluder device (MFO), which is increasingly used. The purpose of this study is to present mid-term results of MFO for transcatheter closure of patients with perimembraneous ventricular septal defect.Patients and methods: Records of the 52 patients with perimembraneous ventricular septal defect who had undergone transcatheter closure with MFO were reviewed. Demographic, echocardiographic, and procedure details were investigated. Three years follow-up results were recorded.Results: We closed the perimembraneous ventricular septal defect in 51 of 52 patients (98%). The femoral venous approach was used in 27 patients (53 %) whilst no arteriovenous loop was established in the remaining patients. No significant procedure-related complication occurred. On day 1 echocardiography, the residual ventricular septal defect rate was 31%. Mean±SD (range) follow-up duration was 36 ± 7,9 (18–54) months. In the follow-up, at 6th months, only four patients had hemodynamically insignificant residual defects. No severe dysrhythmia was detected including complete heart block. A right bundle branch block pattern was seen in one patient.Conclusion: This study showed that MFO is a safe and effective device in the transcatheter treatment of perimembraneous ventricular septal defect’s with mid-term follow-up.